E. coli strain engineering for the production of advanced biopharmaceutical products
Abstract
Since the emergence of the biopharmaceutical industry in the 1980's, Escherichia coli, has played an important role in the industrial production of recombinant proteins and plasmid DNA for therapeutic use. Currently, advanced biopharmaceutical products, including rationally designed recombinant proteins and viral-vector gene therapies, offer unprecedented promise for the long-term management, and even cure of disease. As such, E. coli remains an important production host for the biopharmaceutical industry. This review provides insight into the industrially relevant strain engineering approaches used to enhance both the quantity and quality of these therapeutic products.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
E. coli has fast growth rate (doubling time 20 min), low cost, easiness of genetic manipulation, well-known molecular features, good productivity, and simple fermentation process development for manufacturing scale-up, making it an affordable expression system for recombinant protein.
“Given the fast growth rate (doubling time is 20 min), the low cost (the medium is inexpensive), the easiness of genetic manipulation, the well-known molecular features, the good productivity and the simple fermentation process development for manufacturing scale-up, this microorganism represents an affordable expression system for recombinant protein [43,44,45,46].”
From Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments (2020) · cites this paper as [44]
Cites
Codon bias and heterologous protein expression
Gustafsson, C., Govindarajan, S., & Minshull, J. (2004) · Trends in Biotechnology · doi:10.1016/j.tibtech.2004.04.006 · Cited by 1,330 · see citing works
Production of Biopharmaceuticals in E. coli: Current Scenario and Future Perspectives
Baeshen, M. N., Al-Hejin, A. M., Bora, R. S., Ahmed, M. M. M., Ramadan, H. A. I., Saini, K. S., Baeshen, N. A., & Redwan, E. M. (2015) · Journal of Microbiology and Biotechnology · doi:10.4014/jmb.1412.12079 · Cited by 330 · see citing works
Antibiotic-free selection in biotherapeutics: Now and forever
Mignon, C., Sodoyer, R., & Werle, B. (2015) · Pathogens · doi:10.3390/pathogens4020157 · Cited by 87 · see citing works
Synthetic biology: from hype to impact
Gardner, T. S. (2013) · Trends in biotechnology · doi:10.1016/j.tibtech.2013.01.018 · Cited by 46 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Platforms for Production of Protein-Based Vaccines: From Classical to Next-Generation Strategies
Cid, R., & Bolívar, J. (2021) · Biomolecules · doi:10.3390/biom11081072 · Cited by 176 · see citing works
Evolution of Escherichia coli Expression System in Producing Antibody Recombinant Fragments
Sandomenico, A., Sivaccumar, J. P., & Ruvo, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176324 · Cited by 134 · see citing works
- Authors
- Selas Castiñeiras, T., Williams, S. G., Hitchcock, A. G., & Smith, D. C.
- Affiliations
- Cobra Biologics, Stephenson Building, The Science Park, Keele ST5 5SP, UK
- Corresponding author
- Smith, Daniel C
- Venue
- FEMS Microbiology Letters
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-07-04
- Volume
- 365
- Issue
- 15
- ISSN
- 0378-1097 (ISSN-L)
- 1574-6968
- OpenAlex
- W2884668665
- Cited by
- 92
- References
- 4
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 13 · 2023: 22 · 2022: 25 · 2021: 12 · 2020: 5 · 2019: 4 · 2018: 1
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- FEMS Microbiology Letters (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Microbial Metabolic Engineering and Bioproduction
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Escherichia coli, strain engineering, recombinant protein expression, plasmid DNA production, biopharmaceuticals, rational protein design, viral vector gene therapy, therapeutic proteins
- MeSH terms
- Escherichia coli, Recombinant Proteins, Metabolic Engineering
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
